Prof Dr. Xiaoying Yin, Shanghai University of Engineering Science, China
Prof. Dr. Xiaoying Yin, a distinguished Professor and Doctoral Supervisor at the Shanghai University of Engineering Science, is a leading expert in biomaterials science and traditional Chinese medicine-based drug discovery. Holding a Ph.D. from China Pharmaceutical University, she has made substantial contributions to nanocomposite material development and active ingredient screening. She has led multiple National Natural Science Foundation projects, published over 100 scientific papers, and holds 18 patent applications, including international grants. A recipient of numerous provincial and national innovation awards, Prof. Yin also holds esteemed positions in various professional committees advancing pharmaceutical modernization and clinical translation in China.
Author Profile
Education
Prof. Dr. Xiaoying Yin embarked on her academic journey with a deep passion for pharmaceutical sciences and biomedical innovation. She earned her Ph.D. from China Pharmaceutical University, one of the nation’s most prestigious institutions in drug development and pharmacology. Her early research reflected a strong inclination toward traditional Chinese medicine (TCM) and advanced chemical engineering, laying a solid foundation for her future interdisciplinary work. Her academic pursuits during her formative years not only shaped her scientific thinking but also ignited her lifelong interest in integrating modern materials science with traditional therapeutic principles.
Experience
Currently serving as a Level 3 Professor and Doctoral Supervisor at the School of Chemistry and Chemical Engineering / Institute for Frontier Medical Technology, Shanghai University of Engineering Science, Prof. Yin is recognized as a pillar in both academia and applied research. Her leadership extends beyond teaching, into pioneering research in biomaterials, nanocomposites, and drug discovery from TCM.
She has also enriched her global perspective through academic exchange as a Senior Visiting Scholar at the School of Pharmaceutical Sciences, Peking University, broadening her network and influence in national-level pharmaceutical sciences.
In addition to her institutional roles, she holds multiple influential appointments, including:
-
Standing Committee Member, Chinese Medicine Analysis Branch of the China Association of Chinese Medicine 🧪
-
Council Member, Health Industry Branch, China Association of National Medicine 🏥
-
Standing Professional Committee Member, Clinical Translation of Pharmaceutical Modernization 🧬
Research Focus
Prof. Yin has consistently contributed to the advancement of biomaterials science, nanocomposite material development, and the screening and identification of active compounds in traditional Chinese medicine. Her research is characterized by a unique blend of traditional knowledge and modern scientific methods, which she leverages to identify lead compounds with potential therapeutic applications.
🔬 Over the years, she has:
-
Led four major projects funded by the National Natural Science Foundation of China (NSFC)
-
Participated in three national key science and technology support programs
-
Directed over 10 provincial/ministerial-level research projects
She has authored 100+ academic publications, including 60+ SCI and EI-indexed journal papers. Her extensive research portfolio demonstrates both the depth and breadth of her contributions to pharmaceutical sciences.
Award and Recognition
Prof. Yin’s outstanding work has been recognized through numerous awards and honors:
-
Provincial Natural Science Award (Second Prize) 🏅
-
Two Provincial Science and Technology Progress Awards 🔬
-
Innovation Achievement Awards from national-level academic associations
-
Second and Third Prize for Innovation in Higher Education Institutions 🎓
In addition to publishing extensively, she has:
-
Applied for 18 domestic and international invention patents, including 2 PCT patents
-
Received 11 granted patents, including 2 international patents approved in the UK and other countries
Publications
📘Molecular Mechanisms of Reversal of Multidrug Resistance in Breast Cancer by Inhibition of P-gp by Cytisine N-Isoflavones Derivatives Explored Through Network Pharmacology, Molecular Docking, and Molecular Dynamics – International Journal of Molecular Sciences(2025).
📘Exploring drug repositioning possibilities of kinase inhibitors via molecular simulation – Molecular Informatics(2024).
📘Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery – Journal of Chemical Information and Modeling(2024).
📘Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia – Biomedicine and Pharmacotherapy(2023).